RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
RIGEL PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$46.72+0.75 (+1.63%)
Close on Oct 19, 2026
- Market cap
- $914.31M
- P/E (TTM)
- 2.9
- Dividend yield
- –
RIGEL PHARMACEUTICALS INC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single reportable segment | $78.70M | $58.82M | – | – | $101.69M | $53.33M | – | – | – | – | – | – | 100.0% | -22.6% |
| Single reportable segment | – | – | $69.80M | $69.46M | $101.69M | $53.33M | $57.60M | $55.31M | $36.84M | $29.53M | – | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross product sales | $88.46M | $75.39M | $84.45M | $85.62M | $79.69M | $60.19M | $66.20M | $56.32M | $48.98M | $38.43M | $41.82M | $38.59M | 112.4% | +11.0% |
| Product sales, net | $67.02M | $54.92M | $65.42M | $64.07M | $58.95M | $43.55M | $46.52M | $38.93M | $33.45M | $26.00M | $29.54M | $27.13M | 85.1% | +13.7% |
| Contract revenues from collaborations and other | $11.69M | $3.90M | $4.12M | $5.40M | $42.74M | $9.78M | $11.07M | $16.38M | $3.39M | $3.53M | $6.15M | $1.01M | 14.9% | -72.7% |
| Delivery of drug supplies, royalties and others | $7.69M | $3.90M | $4.12M | $5.40M | $2.76M | $6.78M | $7.07M | $6.38M | $3.39M | $3.53M | $6.15M | $930.00K | 9.8% | +179.0% |
| Development Milestones | $4.00M | $0 | $0 | $0 | $0 | $3.00M | – | – | – | – | $0 | $75.00K | 5.1% | – |
| Release of cost share liability | $0 | – | – | – | $39.98M | – | – | – | – | – | – | – | 0.0% | -100.0% |
| Discounts and allowances | -$21.45M | -$20.47M | – | -$21.56M | -$20.74M | -$16.64M | – | -$17.40M | -$15.53M | -$12.42M | – | -$11.46M | -27.3% | +3.4% |
| Government contracts | – | – | – | – | – | – | – | – | – | – | $100.00K | $0 | – | – |
| License revenue | – | – | – | – | – | – | $4.00M | $10.00M | – | – | – | – | – | – |
| Release of cost share liability | – | – | – | $0 | $39.98M | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Rigel Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.